Jackie Walling, M.d., Ph.D.
Chief Medical Officer
Jackie Walling, M.D., Ph.D., serves as the company’s chief medical officer (CMO). With over 30 years of clinical oncology, she has a storied career of leading clinical development of new drugs for rare diseases.
Prior to her work with FLAG, Dr. Walling was the vice president of BioMarin where she led clinical development for an array of drugs for both rare genetic diseases and oncology. She was responsible for multiple worldwide studies at all stages of development (I to IV) and significantly contributed to successful regulatory interactions.
As medical director at Tularik and then as vice president, clinical research at Axys Pharmaceuticals, Dr. Walling defined and implemented worldwide clinical/product development strategy across different therapeutic areas.
Dr. Walling worked at Eli Lilly as the director, science and operations (oncology) where she was responsible for overall clinical and scientific strategy implementation for two novel antifolate compounds, one of which is now licensed in the treatment of mesothelioma and secondline NSCLC. Prior to her work as director, Dr. Walling worked for 7 years in various clinical oncology roles in increasing responsibility for Lily Industries.
Aleem Gangjee, Ph.D.
Scientific Director, AA/AT Program
Aleem Gangjee, Ph.D., serves as the scientific director for the Anti-angiogenic & Anti-tubulin (AA/AT) platform. A distinguished professor of medicinal chemistry at the Duquesne University School of Pharmacy, Dr. Gangjee is an internationally renowned scientist and author of dozens of U.S. and international patents. As a researcher, his broad expertise spans synthetic medicinal chemistry, computer-assisted drug design, antimitotic agents and antitumor agents.
Dr. Gangjee earned his B.S. in chemistry and M.S. in organic chemistry from the Indian Institute of Technology and his Ph.D. in medicinal chemistry from the University of Iowa. Among his many honors, Dr. Gangjee was named the recipient of the 2012 Research Achievement Award in Drug Discovery and Development Interface from the American Association of Pharmaceutical Scientists (AAPS).
Click here for publications
Larry Matherly, Ph.D.
Scientific Director, PSI program
Larry Matherly, Ph.D., serves as the scientific director for the Purine Synthesis Inhibitor (PSI) platform. He leads studies aimed toward drug discovery and translational studies of chemotherapy response and resistance. Dr. Matherly has been instrumental in the development of FLAG’s PSI platform and continues to push the first-in-class technology in new, innovative directions. His research has long focused on studies of transport processes for natural folates and folate analogs. These include the widely expressed reduced folate carrier (RFC), the proton-coupled folate transporter (PCFT) and the high affinity folate receptors (FRs).
In addition to his work with FLAG, Dr. Matherly serves as the associate center director for basic sciences at Karmanos Cancer Institute, the leader of the Molecular Therapeutics (MT) Program at Karmanos and as a professor in the Department of Oncology at Wayne State University School of Medicine.
Dr. Matherly earned his B.S. in biology from New Mexico State University and his Ph.D. in biochemistry from Pennsylvania State University. He was awarded the 2016 Eunice and Milt Ring Endowed Chair for Cancer Research.
Click here for publications
James Bauler, M.A.
Director, Corporate Development
James Bauler, director of corporate development, has 20 years’ career experience building multinational organizations. James has held roles, including in government affairs, business development and corporate development, in early-stage healthcare companies . James completed his master’s degree in international relations at the Tufts University Fletcher School of Law and Diplomacy and his B.A. in business investment finance at Wheaton College.
Connect with James
Beth A. Slusar
Director, Program Management
Beth Slusar is currently FLAG’s Director of Program Management and has over 25 years of experience working in the pharmaceutical industry. Before joining FLAG in 2014, Ms. Slusar was Director of Project Management at Cirrus Pharmaceuticals, a contract research organization, where she and her group managed all programs internally within Cirrus and served as the single point of contact with all clients. Prior to Cirrus, she was a Project Manager at DPT Laboratories and at Phyton Biotech, a company which pioneered the production of taxanes from plant cell fermentation. While at Phyton, Ms. Slusar spent 15 years in positions ranging from analytical sciences, quality control, plant cell strain development, research and project management. Ms. Slusar received her degree in Chemistry from the State University of New York, Oswego.